Cipla Ltd. — Capital/Financing Update 2020

Feb 10, 2020

Press Release:

==> picture [87 x 30] intentionally omitted <==

CIPLA SA SIGNS AGREEMENT FOR ANTI-PSYCHOTIC DRUG

Cape Town, 10 February 2020: As part of its quest to provide access to life-saving medication and making a difference in the lives of patients, Cipla Medpro South Africa (Pty) Limited (“ Cipla Medpro ”), wholly-owned subsidiary of Cipla Limited, India (“ Cipla ”) and South Africa’s third largest pharmaceutical company in the private sector, has recently concluded an exclusive agreement (the “Agreement”) securing originator and authorised generic brands of an atypical anti-psychotic drug, Quetiapine (the “Medicine”).

The agreement involves AstraZeneca Pharmaceuticals (Pty) Limited, the originator of the Medicine, and Luye Pharma Hong Kong Limited, which acquired the assets and rights to the medicine in select territories. The transaction allows Cipla Medpro to market and distribute the Medicine in South Africa and neighbouring countries.

The existing portfolio consists of the originator brand Seroquel[®] and the authorised generic brand Truvalin[®] , medication which is used to treat mental health conditions such as schizophrenia, bipolar disorder, and major depressive disorder.

Paul Miller, CEO of Cipla South Africa, said the agreement strategically enhances Cipla’s Central Nervous System (CNS) portfolio: “We want people to live a long and healthy life and have invested significantly in public awareness campaigns to educate people about the importance of mental health and the fact that there is help and hope. This transaction will help ensure that people have access to affordable and quality medicine that will help improve quality of life for people living with these conditions.”

“This partnership amplifies Cipla’s growing intent to partner with innovator companies and this is a further demonstration of our core competence in building and growing originator brands, ably strengthened by strong corporate governance and quality mindset,” said Miller.

ENDS

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec’19), 3rd largest in the pharma private market in South Africa (IQVIA MAT Dec’19), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigmchanging offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit Cipla, or click on Twitter, Facebook, LinkedIn.

About Cipla South Africa:

Cipla Medpro South Africa (Pty) Limited (“ Cipla Medpro ”) is a wholly owned subsidiary of Cipla Limited, India (“ Cipla ”) and third largest pharmaceutical company in the private sector in South Africa. Through Cipla’s ethos of ‘Caring for Life’, Cipla Medpro produces world-class medicines at affordable prices for the public and private sectors, advancing healthcare for all South Africans.

For more information, visit www.cipla.co.za/

Media Contact

Corporate Communications Investor Relations Heena Kanal Naveen Bansal E-Mail: CorpComm@cipla.com E-Mail: Investor.Relations@cipla.com